TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women-18 to 55 years of age.~* There are three groups of volunteers.~  * Group A. People who are hypertensive with kidney disease. When not taking blood pressure medicines, blood pressure must have a systolic between 140-170 mmHg. Diastolic must be between 90-109 mmHg.Kidney function should be around half of normal. Urine protein must be no more than 1 gram in a 24-hour urine time period.~ * Group B. People who are hypertensive without kidney disease. Blood pressure must have a systolic between 140-170 mmHg. Diastolic must be between 90-109 mmHg. Kidney function should be normal. Normal amounts of protein in their urine.~ * Group C. People who are normotensive. Blood pressure must have a systolic below 131/mmHg. Diastolic must be below 81 mmHg. Kidney function should be normal. No more than normal amounts of protein in their urine.~Exclusion Criteria:~People with:~* Diabetes~* Lung disease~* Stomach disease~* Liver disease~* Blood vessel disease~* Heart disease~* Hereditary blood disorders~* Hematocrit (amount of red blood cells) less than 30%~* Current tobacco use~* Kidney disease who require dialysis~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CKD (Type: EXPERIMENTAL): None
- Hypertension group (Type: ACTIVE_COMPARATOR): None
- Normotensive group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ARDS Esophageal Balloon Pressure Changes With Positioning Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age at least 18 years old, need for mechanical ventilation, moderate or severe ARDS, and the ability to tolerate prone positioning.~Exclusion Criteria will be patients who:~* are deemed too ill by their clinicians to be included in the study~* have esophageal or nasopharyngeal pathology (such as tumors, sinusitis, epistaxis, ulcerations, recent surgery or bleeding varices) preventing insertion of the esophageal balloon catheter~* diverticulitis~* bronchopulmonary fistula~* solid-organ transplantation~* history of difficult intubation or airway management~* or contraindications to prone positioning (per the UNC Medical Intensive Care Unit Pronation Therapy protocol, attached)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esophageal balloon catheter placement (Type: None): This is the primary and only arm of the study in which acute respiratory distress syndrome patients will have an esophageal balloon catheter placed with pressures recorded in the supine, upright and prone positions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 years of age or older~* Must currently be on ACE inhibitor therapy and have received a dose within 36 hours~* Presenting with ACEIA of the head/neck region within 12 hours after onset~* All females must have a negative urine pregnancy test prior to administration of the study drug. Those who have had a total hysterectomy, bilateral oophorectomy or are two years post-menopausal do not require a pregnancy test.~Exclusion Criteria:~* Hypersensitivity to ecallantide~* Pregnancy or breast feeding~* Patients who have had angioedema and were not concurrently on an ACE inhibitor~* Patients exhibiting urticaria~* Patients who are intubated or who have a tracheostomy related to the current episode of angioedema~* Opinion of the investigator that the patient would not be a good candidate~* Participation in another investigational study within 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ecallantide 10mg (Type: ACTIVE_COMPARATOR): Administered as one 3 mL SC injection containing 10 mg ecallantide and one 3 mL SC injection of matching placebo.
- placebo (Type: PLACEBO_COMPARATOR): Administered as two SC 3 mL injections
- ecallantide 60mg (Type: ACTIVE_COMPARATOR): Administered as two 3 mL SC injections, each containing 30 mg ecallantide
- ecallantide 30mg (Type: ACTIVE_COMPARATOR): Administered as one 3 mL SC injection containing 30 mg ecallantide and one 3 mL SC injection of matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Esophageal Balloon Guided Weaning of the Morbidly Obese Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Morbidly obese patients with BMI of 40 or greater~* Ventilator dependent patients (defined as at least one prior failure at weaning)~* Tracheotomized~* No active underlying lung disease that would preclude ventilator weaning~* Stable hemodynamics~* Patient/ family able to give consent~* No naso-facial abnormalities that would interfere with placement of an esophageal balloon~* Fio2 \<= 60%~* Patient able to tolerate Pressure Support ventilation~Exclusion Criteria:~* Lack of consent~* Patient deemed not weanable from mechanical ventilation as per the clinical judgement of the pulmonary physician~* Significant lung, heart or neuromuscular disease that would interfere with or preclude ventilator weaning, including an active ongoing lung infection.~* Contraindications to placement of an esophageal pressure monitoring device - such as ulcerations, tumors, diverticulitis, uncontrolled bleeding varices, sinusitis, epistaxis or recent nasopharyngeal surgery

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esophageal balloon Arm (Type: ACTIVE_COMPARATOR): Patients in this arm were randomly assigned to have their PEEP adjusted to maintain a positive transpulmonary pressure (0 to 10 cm H20).
- Cstat Arm (Type: ACTIVE_COMPARATOR): Patients in this arm had their PEEP adjusted to achieve the best static effective compliance (CStat).
- Historic Controls (Type: NO_INTERVENTION): These were historic controls with similar patient characteristics weaned by traditional methods in the 2-year period prior to the start of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the PedSCath Pediatric Sampling Catheter Versus Current Standard of Care.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is 3 years of age or younger.~* Subject is non-toilet trained, as communicated by subject's parent/guardian.~* Subject is presenting to the emergency department with symptoms for UTI, as described by AAP guidelines (Newborns with UTI may present with jaundice, sepsis, failure to thrive, vomiting, or fever. In infants and young children, typical signs and symptoms include fever, strong-smelling urine, hematuria, abdominal or flank pain, and new-onset urinary incontinence) or as determined by PI.~* Subject's parent/guardian is able to provide informed consent.~Exclusion Criteria:~* Any subject with known underlying abnormalities to the genitourinary tract (e.g. prenatal hydronephrosis).~* Any subject who has had prior genitourinary tract or abdominal surgery.~* Any subject who is toilet trained (i.e. able to provide a clean catch urine sample).~* Any subject with an active rash or skin lesion in the suprapubic area.~* Any subject with a known allergy to LDPE, Elvax, or Crodamide plastics.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- PedSCath (Type: None): Subjects in this arm will be catheterized with the PedSCath Pediatric Urinary Cather.
- Retrospective Control (Type: None): Generated from 2016 and 2018 anonymized subject data from the clinical sites.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~I- PATIENTS~* men or women~* who have been informed about the study~* and who have provided verbal consent to take part in the study~* able to understand written and spoken French~* with non-resectable metastatic cancer of: the colon, or the rectosigmoid junction or the stomach or bile ducts or rectum or gastrointestinal neuroendocrine tumor or lung (not small-cell cancer) or pancreas~* with a caregiver designated as the principal caregiver (family, friend, neighbour)~* who has consented to the principal caregiver taking part in a qualitative interview~* able to take part in an interview lasting roughly one hour~II- CAREGIVERS~* men or women~* who have been informed about the study~* who have provided verbal consent to take part in the study~* able to understand written and spoken French~* able to follow an interview lasting roughly one hour~III-DOCTORS~* men or women~* who have been informed about the study~* who have provided verbal consent to take part in the study~* specialised in specific organ or oncologist prescriber~Exclusion Criteria:~I- PATIENTS~* under guardianship or ward of court~* with a severe handicap (neurological disease: Parkinson, Alzheimer, other dementia, multiple sclerosis, severe mental retardation etc.)~II- CAREGIVERS~* under guardianship or ward of court,~* with a severe handicap (neurological disease: Parkinson, Alzheimer, other dementia, multiple sclerosis...),~* with severe mental retardation impairing ability to understand.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Stable patients, early responders to treatment and caregivers (Type: None): None
- Stable patients and intermediate responders and c (Type: None): Stable patients and intermediate responders to treatments and caregivers
- Doctors (Type: None): None
- Patients in therapeutic escape and their caregivers (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female (negative pregnancy test required for females of childbearing potential) ≥ 18 years of age and capable of signing informed consent;~* Typical chest discomfort at rest; lasting at least 5 minutes in the prior 24 hours that is highly suggestive of myocardial ischemia and is not explained by trauma or obvious abnormalities on chest x-ray;~* Two or more of high-risk clinical features.~Exclusion Criteria:~* Clear indication for low molecular weight or unfractionated heparin;~* Pregnancy;~* Increased bleeding risk;~* Impaired hemostasis;~* Angina from a secondary cause;~* Inability to commence ST segment monitoring within 4 hours of study drug initiation;~* Uninterpretable ST segment based upon baseline 12-lead ECG;~* Any contraindications to treatment with LMWH (or unfractionated heparin), including heparin induced thrombocytopenia, known allergy to heparin, low molecular weight heparin, pork or pork products;~* Renal insufficiency or renal dialysis;~* A prosthetic heart valve;~* Any other clinically relevant serious diseases;~* Current evidence of inebriation with alcohol or intoxication resulting from other drug abuse;~* Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or has previously enrolled in this trial;~* Inability to comply with the protocol;~* Inability to understand the nature, scope, and possible consequences of the study or is otherwise unable to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Monitoring Glucose Levels in Patients With Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute coronary syndrome according to the joint recommendations by the European Society of Cardiology (48, 49)~* Signed written informed consent consistent with Helsinki declaration and local legislations prior to participation in the trial.~Exclusion Criteria:~* \<18 years old.~* Congestive heart failure.~* Patients who, in the opinion of the investigator, will have difficulties to comply with the protocol (examples: alcohol or drug abuse, psychiatric disorder).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glucose monitoring by OptiScanner® (Type: OTHER): Glucose monitoring and intervention guided by OptiScanner®
- Blinded continuous glucose monitoring (Type: OTHER): Blinded continuous glucose monitoring by OptiScanner® and glucose lowering intervention guided by routine glucose measurements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Beta Cell Imaging in T1D Patients With a Different Glycemic Control

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Group 1 (stable glycemic control)~* Age ≥18 years~* T1D diagnosed ≥1 year at the start of the study~* HbA1c \<7 (\<53 mmol/mol)~* 17≤ BMI ≤30 kg/m2~* No severe hypoglycemic events in the past year and a maximum of 2 severe hypoglycemic events in their entire life.~* Intact hypoglycemic awareness~* Ability to sign informed consent~Group 2 (unstable glycemic control) Age ≥18 years~* T1D diagnosed ≥1 year at the start of the study~* HbA1c \>8.5 (\>69 mmol/mol)~* 17≤ BMI ≤30 kg/m2~* Minimum of 2 severe hypoglycemic events in the past year, or an impaired awareness of hypoglycemia (subjects may comply with both criteria, but this is not a requirement)~* Ability to sign informed consent~Exclusion Criteria:~* Previous treatment (within 6 months) with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors~* Liver disease~* Renal disease~* Pregnancy or the wish to become pregnant within 6 months after the study~* Breastfeeding~* BMI \<17 kg/m2 or BMI \>30 kg/m2~* Age \<18 years~* Inability to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with stable near-normal T1D (Type: None): * Mixed-meal tolerance test~* Intravenous injection with gallium-68-exendin followed by a PET/CT scan
- Subjects with unstable T1D (Type: None): * Mixed-meal tolerance test~* Intravenous injection with gallium-68-exendin followed by a PET/CT scan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Slings and Their Effect on Skin Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* need assistance with mobility, using any patient handling equipment~* are ≥ 18 years of age~* are English speaking or guardian is English speaking~* are medically stable~Exclusion Criteria:~* have positional hypotension~* are on aspiration precautions~* are paralyzed~* have neuromuscular disease~* have below the knee amputation(s)~* weigh greater than 500 lbs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1-6 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of multiple sclerosis, known or suspected diagnosis of glioma, or known or suspected diagnosis of cerebral metastasis~* Scheduled or to be scheduled for a follow-up MRI per standard of care for their disease~* Minimum permitted time intervals from prior treatments are 6 weeks for intracranial surgery~* Adequate renal function (serum creatinine =\< 1.5 mg/dL)~* Subject must sign a study-specific informed consent~Exclusion Criteria:~* Medically unstable~* Renal impairment (glomerular filtration rate \[GFR\] \< 60 mL/min/1.73m\^2) or history of existing nephrogenic systemic fibrosis (NSF)~* Cardiac pacemaker~* A serious concurrent infection, illness, or medical condition~* Subjects with any surgical clip, external clips, or any other ferromagnetic device, that is contraindicated for use in MRI~* Subject is claustrophobic and cannot cooperate for the MRI~* Females who are pregnant or nursing~* Any other condition that would compromise the scan with reasonable safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (Magnevist/Multihance, Gadavist, DCE-MRI) (Type: EXPERIMENTAL): Patients receive standard of care gadopentetate dimeglumine IV twice within 5 minutes or gadobenate dimeglumine IV twice within 5 minutes and then undergo DCE-MRI on day 1. Patients also receive gadobutrol IV twice within 5 minutes and then undergo DCE-MRI over approximately 30 minutes on day 3, 4, 5, 6, or 7.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 years or older~* Fluency in English~* African American~* HbA1C\>8%~Exclusion Criteria:~* Subjects with no web access,~* Subjects using an insulin pump,~* Subjects that are pregnant~* Subjects that have active substance abuse including alcohol,~* Subjects with visual impairment or have severe hearing or other physical disabilities that would be a barrier for participating in-group or web sessions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group-based Cognitive Behavioral Intervention (Type: EXPERIMENTAL): Subjects receiving the group-based CT-CB intervention
- Web-based Cognitive Behavioral Intervention (Type: EXPERIMENTAL): Subjects receiving the web based CT-CB intervention
- Usual Care (Type: PLACEBO_COMPARATOR): Subjects receiving usual care from their primary care providers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symmetrical keratometric astigmatism ≥ 1.0 D and cataract.~Exclusion Criteria:~* Irregular astigmatism,~* Keratoconus,~* Previous Refractive Surgery.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Acrysof Toric intraocular lens (Type: EXPERIMENTAL): A One piece, acrylic intraocular lens is implanted in the lens bag.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues